News
DERM
8.04
-3.71%
-0.31
Weekly Report: what happened at DERM last week (0202-0206)?
Weekly Report · 17h ago
Weekly Report: what happened at DERM last week (0126-0130)?
Weekly Report · 02/02 10:21
Weekly Report: what happened at DERM last week (0119-0123)?
Weekly Report · 01/26 10:21
BRIEF-Journey Medical Corp Entered Into Sales Agreement To Offer And Sell Up To 3.75 Million Shares Of Common Stock
Reuters · 01/23 21:33
Journey Medical Files $3.75M At-The-Market Common Stock Offering With B. Riley And Lake Street
Benzinga · 01/23 21:13
JOURNEY MEDICAL CORP: ENTERED INTO SALES AGREEMENT TO OFFER AND SELL UP TO 3.75 MLN SHARES OF COMMON STOCK - SEC FILING
Reuters · 01/23 21:11
Journey Medical: Emrosi Is Winning, But The Stock Hasn't Noticed
Seeking Alpha · 01/23 01:43
Weekly Report: what happened at DERM last week (0112-0116)?
Weekly Report · 01/19 10:27
Closing Bell Movers: JB Hunt down over 4% after soft Q1 sales
TipRanks · 01/16 00:40
Journey Medical Files For Mixed Shelf Of Up To $150M
Benzinga · 01/15 21:46
JOURNEY MEDICAL CORP FILES FOR MIXED SHELF OF UP TO $150 MLN - SEC FILING
Reuters · 01/15 21:44
Weekly Report: what happened at DERM last week (0105-0109)?
Weekly Report · 01/12 10:26
Journey Medical Corp (DERM) Gets a Buy from Lake Street
TipRanks · 01/05 13:45
Weekly Report: what happened at DERM last week (1229-0102)?
Weekly Report · 01/05 10:20
Weekly Report: what happened at DERM last week (1222-1226)?
Weekly Report · 12/29/2025 10:20
Weekly Report: what happened at DERM last week (1215-1219)?
Weekly Report · 12/22/2025 10:20
Weekly Report: what happened at DERM last week (1208-1212)?
Weekly Report · 12/15/2025 10:27
Journey Medical announces results from Phase 1 trial of DFD-29
TipRanks · 12/10/2025 13:50
Journey Medical Reports Emrosi Shows No Impact on Microbiome in Phase 1 Trial
Reuters · 12/10/2025 13:30
JOURNEY MEDICAL CORPORATION ANNOUNCES PUBLICATION OF CLINICAL TRIAL RESULTS ASSESSING THE IMPACT OF EMROSI™ (DFD-29) ON MICROBIAL FLORA OF HEALTHY ADULTS IN THE JOURNAL OF DRUGS IN DERMATOLOGY
Reuters · 12/10/2025 13:30
More
Webull provides a variety of real-time DERM stock news. You can receive the latest news about Journey Medical Corp through multiple platforms. This information may help you make smarter investment decisions.
About DERM
Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.